Here's the hot stuff from Krystal Biotech
$KRYS (-0,17%) (NASDAQ: KRYS) Q2 2026 Earnings Release, delivered fresh from Pittsburgh just before the U.S. market close:
🚀 Top-Line Performance & VYJUVEK Booster
Krystal Biotech continues to ramp up its gene-based skin therapy in the second quarter of 2026. The growth is driven almost exclusively by the best-selling product VYJUVEK (for the treatment of the rare skin disease DEB):
Revenue (VYJUVEK Net Revenue): Climbed by +24% YoY to $119.2 million (compared to 96.0 million USD in the same quarter of the previous year). Since its launch, the drug has already generated $965.9 million have been generated!
Distribution & Prescriptions: The prescriber network grew to over 640 unique physicians. In addition, over 730 reimbursement commitments (reimbursements) have already been secured worldwide.
Top-line caveat: Analysts had set the bar extremely high in the run-up to the earnings report, with expectations of ~$122–126 million. The slight miss on the revenue side triggered a mild “sell the news” reaction on the stock market, despite strong overall figures.
đź”® Profitability Leaps & EPS Beat
While many biotech companies are burning through cash, Krystal Biotech is generating real cash with fantastic margin figures:
Fantastic Margins: The gross margin remained rock-solid at a phenomenal 95%!
Net Income (GAAP): Soared by +43% year-over-year to 54.77 million USD (previous year: $38.33 million).
EPS beat: Earnings per share (diluted EPS) climbed to $1.79 (previous year: $1.29), significantly exceeding the analyst consensus of $1.70–$1.73!
🤖 Pipeline Expansion & Rock-Solid Balance Sheet
Balance Sheet as Solid as a Rock: The coffers are overflowing. At the end of Q2, Krystal sat on a whopping $1.1 billion in cash and investments—ensuring the pipeline is fully funded for years to come.
Geographic Expansion: The market launches of VYJUVEK in Spain and Italy are scheduled for the second half of 2026.
Pipeline catalysts: Over the next 12 to 18 months, key Phase 3/registration data for additional indications in the areas of the eye, lung, and skin are expected.
⚡ 💡 Jack’s Conclusion
Not some highly speculative biotech “hope-and-dream” construct, but a cash machine! The fact that the market is slightly selling off the stock today due to a minimal revenue miss (–$2 million vs. consensus) is nitpicking at an extremely high level. A gross margin of 95%, $1.1 billion in cash on hand, and an EPS beat with +43% net income growth show exactly what a profitable monopoly in the biotech sector looks like!
What’s your take @Tenbagger2024 ? You’re invested, after all 👀
